1. Low chikungunya virus seroprevalence two years after emergence in Fiji
- Author
-
Alasdair D Henderson, Van-Mai Cao-Lormeau, Colleen L. Lau, Conall H. Watson, Ketan S. Christi, Teheipuaura Mariteragi-Helle, Tuterarii Paoaafaite, Adam J. Kucharski, Jessica Vanhomwegen, Mike Kama, Jean-Claude Manuguerra, Maite Aubry, Anita Teissier, Institut Louis Malardé [Papeete] (ILM), Institut de Recherche pour le Développement (IRD), Fiji Centre for Communicable Disease Control [Suva, Fidji], London School of Hygiene and Tropical Medicine (LSHTM), Institut Pasteur [Paris] (IP), The University of the South Pacific [Suva, Fidji], Australian National University (ANU), This work was supported by the French ministry for Europe and Foreign Affairs [Pacific Funds grant no. 04917-19/07/17], the French Government's 'Investissement d'Avenir' Program [Labex IBEID grant no. ANR-10-LABX-62-IBEID], and the Wellcome Trust [Grant no. 107778/Z/15/Z]. The study also received support from France and French Polynesia governments’ 'Contrat de Projets' [MA’I’ORE program, grants no. HC/372/DIE/BPT-18/05/18 and no. 03298/MTF/REC-17/05/18]. CHW was supported by the UK Medical Research Council [grant no. MR/J003999/1] and is supported by a UK National Institute for Health Research Epidemiology for Vaccinology [grant no. PR-OD-1017-20002]. CLL was supported by an Australian National Health and Medical Research Council Fellowship [grant no. 1109035]. ADH was supported by a Medical Research Council LID studentship [grant no. MR/N013638/1]. AJK was supported by a Wellcome Trust/Royal Society Sir Henry Dale Fellowship [grant no. 206250/Z/17/Z]., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), and Institut Pasteur [Paris]
- Subjects
Immunity, Herd ,Male ,0301 basic medicine ,Ross River ,Seroprevalence ,MESH: Chikungunya Fever ,Antibodies, Viral ,medicine.disease_cause ,0302 clinical medicine ,MESH: Aged, 80 and over ,Seroepidemiologic Studies ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,MESH: Child ,030212 general & internal medicine ,Chikungunya ,MESH: Fiji ,Child ,Aged, 80 and over ,Arbovirus ,MESH: Aged ,education.field_of_study ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,MESH: Middle Aged ,MESH: Immunity, Herd ,Transmission (medicine) ,virus diseases ,General Medicine ,Middle Aged ,3. Good health ,Infectious Diseases ,Seroconversion ,MESH: Young Adult ,Child, Preschool ,Cohort ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Female ,Chikungunya virus ,Adult ,Microbiology (medical) ,Adolescent ,030106 microbiology ,Population ,MESH: Seroconversion ,Article ,Virus ,lcsh:Infectious and parasitic diseases ,Herd immunity ,Young Adult ,03 medical and health sciences ,medicine ,Humans ,Fiji ,lcsh:RC109-216 ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,education ,Aged ,MESH: Adolescent ,MESH: Humans ,MESH: Seroepidemiologic Studies ,business.industry ,MESH: Child, Preschool ,MESH: Adult ,medicine.disease ,Virology ,MESH: Male ,Pacific ,Chikungunya Fever ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,MESH: Female ,MESH: Antibodies, Viral - Abstract
Highlights • Chikungunya virus (CHIKV) infections were recorded in Fiji between 2015 and 2017. • We performed serological testing on serum from 320 Fijians sampled in 2017. • CHIKV seroprevalence increased from 0.9% in 2015 to 12.8% in 2017. • Of the 198 participants seronegative in 2015, 31 (15.7%) were seropositive in 2017. • Low CHIKV transmission occurred during the two years following emergence in Fiji., Objectives In Fiji, autochthonous chikungunya virus (CHIKV) infection was first detected in March 2015. In a previous serosurvey conducted during October–November 2015, we reported a prevalence of anti-CHIKV IgG antibodies of 0.9%. In the present study, we investigated the seroprevalence of CHIKV two years after its emergence in Fiji. Methods Sera from 320 residents of Fiji recruited in June 2017, from the same cohort of individuals that participated in the serosurvey in 2015, were tested for the presence of IgG antibodies against CHIKV using a recombinant antigen-based microsphere immunoassay. Results Between 2015 and 2017, CHIKV seroprevalence among residents increased from 0.9% (3/333) to 12.8% (41/320). Of the participants with available serum samples collected in both 2015 and 2017 (n = 200), 31 (15.5%) who were seronegative in 2015 had seroconverted to CHIKV in 2017. Conclusions Our findings suggest that low-level transmission of CHIKV occurred during the two years following the emergence of the virus in Fiji. No CHIKV infection has been reported in Fiji since 2017, but due to the presumed low herd immunity of the population, the risk of CHIKV re-emergence is high. Consequently, chikungunya should be considered in the differential diagnosis of acute febrile diseases in Fiji.
- Published
- 2020
- Full Text
- View/download PDF